Results 8,341-8,360 of 14,090 for speaker:Marc MacSharry
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 847. To ask the Minister for Health the number of orphan drugs that have been reimbursed by the HSE for the treatment of rare disease since 2012, in tabular form. [19426/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 848. To ask the Minister for Health the number of orphan drugs that have not been recommended for reimbursement by the HSE since 2012, in tabular form; and if he will make a statement on the matter. [19427/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 849. To ask the Minister for Health the details of each drug currently reimbursed since 2012, in tabular form; the date each drug was submitted for approval; the date of its subsequent commercial entry date; and if he will make a statement on the matter. [19428/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 850. To ask the Minister for Health the details of each orphan drug currently reimbursed since 2012, in tabular form; the date each drug was submitted for approval; the date of its subsequent commercial entry date; and if he will make a statement on the matter. [19429/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 851. To ask the Minister for Health the number of orphan drug applications which, following rapid review assessment by the National Centre for Pharmacoeconomics, NCPE, were recommended for full pharmacoeconomic assessment since 2012, in tabular form; and if he will make a statement on the matter. [19430/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 852. To ask the Minister for Health the number of orphan drug applications recommended for reimbursement based solely on the NCPE’s rapid review process since 2012, in tabular form. [19431/17]
- Written Answers — Department of Health: Medicinal Products Reimbursement (2 May 2017)
Marc MacSharry: 853. To ask the Minister for Health the number of orphan drug applications not recommended for reimbursement by the NCPE at the original submitted price that were subsequently approved for reimbursement following confidential price negotiations, in tabular form; and if he will make a statement on the matter. [19432/17]
- Written Answers — Department of Health: Services for People with Disabilities (2 May 2017)
Marc MacSharry: 879. To ask the Minister for Health if it is now mandatory for the next-of-kin of adults with special needs resident in HSE institutions who have managed their personal finances over the years to hand over the management of these finances to the HSE service providers; and if he will make a statement on the matter. [19493/17]
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: I am sorry I was not present for the opening statement. Matters moved quicker than anticipated this morning. I thank the witnesses for attending. The opening statement mentioned the importance of protecting the confidentiality of survivors. The board meeting of 23 March 2017 confirmed the view that Caranua had the authority, in cases where applicants had not provided receipts, to go...
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: Yes.
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: Has it been done so far in any case?
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: What impact does Ms Higgins think it will have on the survivors?
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: Is the balance wrong?
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: Notwithstanding that Caranua is doing its best and the Comptroller and Auditor General is doing his best under the rules that govern him, is it fair to say the system, as it stands, is inadequate for Caranua to do its work?
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: No, the system. The Comptroller and Auditor General has a job to do which involves receipts, auditing and so forth. Given the delicate job Caranua has, is the system inadequate in providing care for the survivors?
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: I know all of that. However, the answer is yes.
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: That is fine. I will move on. I presume the impact of auditing might add stress.
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: I know that is how the world is. However, the system is inadequate for Caranua to do its job, notwithstanding that the Comptroller and Auditor General has done an excellent job under the rules that govern him.
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: Okay, but that is a nice way of saying it is inadequate. With regard to the €15,000 limit and bearing in mind that some of the matters included in the Act are extensions, home improvements, upgrades and the like, in a layman's view, €15,000 will not cover much work. Realistically, is that limit prohibitively low in terms of the vision and ambition of the types of service...
- Public Accounts Committee: Caranua Financial Statements 2014 and 2015 (13 Apr 2017)
Marc MacSharry: What does that mean?